Penumbra Names Shruthi Narayan as President, Effective September 1, 2025

Penumbra, Inc. has named Shruthi Narayan as its new President, effective September 1, 2025. Narayan has 20 years of experience in the medical device industry and has contributed significantly to Penumbra's growth. She will report directly to Chairman and CEO Adam Elsesser. Narayan was previously head of Penumbra's interventional business, overseeing the company's strategic growth initiatives in neuro and vascular product lines.

Penumbra, Inc. (NYSE: PEN), a leading medical device company specializing in thrombectomy technology, has appointed Shruthi Narayan as its new President, effective September 1, 2025. Narayan, a 20-year veteran of the medical device industry, will report directly to Adam Elsesser, who continues as Chairman and CEO. This appointment follows Narayan's significant contributions to Penumbra's growth, particularly in the interventional business, where she led strategic growth initiatives in both neuro and vascular product lines [1].

Narayan's extensive experience in the medical device sector includes roles at Medtronic, where she worked in engineering, regulatory affairs, and cardiovascular sales. She joined Penumbra in 2013 as a product manager in the stroke franchise and has since played a pivotal role in building and globalizing Penumbra's peripheral vascular division [2]. Narayan holds a BS in Electrical Engineering from Anna University in Chennai, India, and an MS in Biomedical Engineering with a focus on Medical Device Commercialization from the University of Southern California [3].

Elsesser, who will continue in his roles as Chairman and CEO, expressed his confidence in Narayan's abilities. "Shruthi is a dynamic, seasoned leader whose passion for innovation and proven ability to inspire global teams make her the obvious choice for this critical role," he stated. "Her vision and focus on excellence will undoubtedly help sustain Penumbra's exceptional growth and market leadership, expanding access to our life-saving technology to patients around the world" [4].

Penumbra's stock price has been stable, currently trading at $265.77 on the New York Stock Exchange, down $0.23 or 0.09 percent from the previous day [3]. The company's forward-looking statements highlight various risks and uncertainties, including potential competition, regulatory actions, and market fluctuations [4].

References:
[1] https://evtoday.com/news/penumbra-names-shruthi-narayan-as-president
[2] https://www.stocktitan.net/news/PEN/penumbra-inc-names-shruthi-narayan-as-company-81iefk7d1yqr.html
[3] https://www.nasdaq.com/articles/penumbra-names-shruthi-narayan-president-drive-global-growth
[4] https://www.biospace.com/press-releases/penumbra-inc-names-shruthi-narayan-as-company-president